Axiom Investors’s ResMed RMD Stock Holding History

Axiom Investors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,699	Closed	-$1.75M	–	129
2021 Q4	$1.75M	Buy	+6,699	New	+$1.74M	0.03%	111

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Axiom Investors's RMD Position: Q1 2022 in Review

Axiom Investors sold out of ResMed (RMD) in Q1 2022, closing a stake of 6,699 shares — an estimated $1.75M sold.

Axiom Investors first reported a position in RMD in Q4 2021 and held it in 1 quarter. The position peaked at $1.75M in Q4 2021. 682 funds tracked by Wall St. Rank hold RMD as of Q1 2022.

Axiom Investors reported no remaining ResMed position as of Q1 2022 after selling out during the quarter.
Axiom Investors sold 6,699 ResMed shares in Q1 2022, an estimated $1.75M.
Axiom Investors first reported a position in ResMed in Q4 2021 and held it in 1 quarter.
Axiom Investors's ResMed position peaked at $1.75M in Q4 2021.
682 funds tracked by Wall St. Rank held ResMed as of Q1 2022.

Based on Axiom Investors's 13F filing for Q1 2022, filed 13 May 2022.